$AIP

Alpern Paul L sold $216K of AIP

Alpern Paul L (VP and General Counsel) sold 6,003 shares of Arteris, Inc. (AIP) at an average of $35.91 ($35.11–$37.13, $0.22M total) across 3 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Alpern Paul L
Published Jul 8, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AIP
Neutral
high confidence
Mentioned
$AIP
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AIPNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the issuer’s VP and General Counsel, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure lacks new fundamental information.

03

What to watch

The article does not include any concurrent buy/sell by other insiders, changes in guidance, or new disclosures that would connect the sale to business performance.

Relevance 3/10Novelty 3/10Timing: after-hours, filed July 8 for trades executed July 6

Background

The article is an SEC Form 4 insider transaction disclosure for Arteris, Inc. (AIP).

Company-level read

Ticker impact

$AIPNeutralHigh confidence
Context

Arteris’ VP and General Counsel sold 6,003 shares in open-market trades totaling about $215.6K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider transaction, but it specifies a pre-arranged 10b5-1 plan and provides no new company-specific operational or financial catalyst.

Market effects

No sector read-through provided; transaction is company-specific and small relative to typical sector flows.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact if it treats it as discretionary selling.

Key entities

  • Arteris, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Alpern Paul L

    VP and General Counsel who sold 6,003 shares under a 10b5-1 plan.

Related articles

MedAI 8/10

Arteris Inc. raises FY26 sales guidance to $95-98M range

Arteris Inc. raised its FY2026 revenue guidance to $95.0 million to $98.0 million, up from $91.0 million to $95.0 million previously. The new range is above the $94.578 million analyst consensus estimate, reflecting stronger-than-expected demand for its NoC interconnects and design automation tools, according to the company.

$AIPHighAI 9/10

Arteris, Inc. (AIP): Results of Operations and Financial Condition

Arteris, Inc. (AIP) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2fy268-k.htm EX-99.1 Document Arteris Announces Financial Results for the Second Quarter and Estimated Third Quarter and Updated Full Year 2026 Guidance CAMPBELL, Calif. - August 6, 2026 - Arteris, Inc. (Nasdaq: AIP), a leading provider of semiconductor techn